Procept Releases Financial Guidance for FY 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy PRCT?
Source: seekingalpha
- Disappointing Earnings Report: Procept's Q4 GAAP EPS of -$0.53 missed expectations by $0.20, indicating challenges in profitability, while revenue of $76.4 million, up 12% year-over-year, fell short of expectations by $17.3 million, reflecting insufficient market demand.
- FY 2026 Revenue Guidance: The company expects FY 2026 revenue to range between $390 million and $410 million, representing a growth of 27% to 33% compared to the prior year, demonstrating confidence in future growth despite current financial pressures.
- Procedure Growth Forecast: Projected U.S. procedure growth for FY 2026 is expected to be between 39% and 48%, indicating potential for expansion in the medical procedure sector, suggesting optimism about future market demand despite current financial performance.
- Operating Expenses and EBITDA Outlook: The company anticipates operating expenses of approximately $350 million for FY 2026, with adjusted EBITDA losses expected to range from $30 million to $17 million, indicating challenges in cost control and a cautious outlook on future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.030
Low
38.00
Averages
51.75
High
65.00
Current: 23.030
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Procept Scheduled to Announce Q1 Earnings with Mixed Estimates
- Earnings Announcement Date: Procept (PRCT) is set to release its Q1 2023 earnings on April 29th after market close, with consensus EPS estimate at -$0.56 and revenue estimate at $80.54 million, reflecting a 16.4% year-over-year growth.
- Performance Expectations: Over the past year, Procept has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, indicating stability in revenue but a need for improvement in profitability.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates, with 6 downward adjustments, and similarly, revenue estimates saw no upward revisions but 7 downward adjustments, suggesting market caution regarding the company's future performance.
- Long-term Revenue Goals: Procept has set a revenue target of $390 million to $410 million for 2026, and despite current performance missing expectations, the company aims to enhance its outlook through pricing discipline and commercial realignment, demonstrating confidence in future growth prospects.
See More
Procept Releases Financial Guidance for FY 2026
- Earnings Beat: Procept's Q1 GAAP EPS of $0.56 exceeds expectations by $1.12, indicating strong performance and improved profitability in the surgical robotics market.
- Significant Revenue Growth: The company reported Q1 revenue of $83.13 million, a 20.1% year-over-year increase, surpassing expectations by $2.59 million, reflecting sustained demand in the surgical robotics sector.
- 2026 Financial Guidance: Procept anticipates full-year 2026 revenue between $390 million and $410 million, representing a growth of 27% to 33% compared to the previous year, showcasing a positive outlook for future market conditions.
- Procedure Growth Expectations: The company expects U.S. procedure growth for 2026 to range from 39% to 48%, highlighting strong growth potential in the surgical robotics market and reinforcing its competitive position.
See More
Chicago Capital Increases Stake in PROCEPT BioRobotics
- Increased Holdings: Chicago Capital increased its stake in PROCEPT BioRobotics by 969,592 shares in Q1 2026, valued at approximately $27.32 million, bringing its ownership to 1.46%, indicating confidence in the company's growth potential.
- Stock Volatility: As of April 23, 2026, PROCEPT shares were priced at $24.24, down 56.5% year-over-year, reflecting significant volatility typical in the medical device sector, raising concerns about its profitability.
- Sales Growth: Since 2022, the number of procedures performed using PROCEPT's AquaBeam system surged from 7,400 to 43,000, while the installed base increased from 167 to 718, demonstrating strong market acceptance of its minimally invasive solutions.
- Improved Profitability: Although still unprofitable, PROCEPT's EBITDA margins improved from -91% to -16%, and gross margins rose from 49% to 64%, indicating the potential for future profitability and competitive strength in the market.
See More
Inogen Shares Surge 6.9% Driven by Buy Rating
- Price Surge Reason: Inogen (INGN) shares rose 6.9% in the last trading session to $6.8, with trading volume significantly above average, indicating increased investor interest in the stock.
- Buy Rating Impact: The initiation of a “Buy” rating by Freedom Broker, along with a substantial price target, has attracted new investors, driving the stock's rise and reflecting market confidence in the company's future growth.
- Governance Improvement Signal: The appointment of industry veteran Vafa Jamali to the board and a cooperation agreement with activist shareholder Kent Lake signal stronger strategic alignment and execution oversight, further boosting market confidence.
- Earnings Forecast: Inogen is expected to report a quarterly loss of $0.24 per share, representing a 4% year-over-year change, with revenues projected at $82.4 million, up 0.2%, reflecting the company's stability and potential growth in the medical instruments sector.
See More
Procept BioRobotics Lowers 2025 Revenue Guidance
- Revenue Growth Expectations: Procept BioRobotics guided for $325.5 million in 2025 revenue, projecting a 45% increase, yet reported only $308.1 million, falling short by $17.4 million, which caused shares to drop over 15% in a single day.
- Pricing Strategy Adjustment: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, resulting in a decrease in average selling prices to approximately $3,200 for its core product line, although the CFO stated this would not impede profitability progress.
- Dismal Future Outlook: The FY 2026 revenue guidance of $410 million to $430 million fell below analyst consensus, indicating pressure in market competition and uncertainty in profitability, which could undermine investor confidence.
- Shareholder Rights Protection: Following the stock decline, shareholders of Procept BioRobotics are encouraged to submit their information to discuss legal rights, indicating potential litigation risks for the company that may further impact its market reputation.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Participants: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Collaborative Advantages: By collaborating with Mayo Clinic and Sutter Health, Sonder Capital can leverage insights from frontline care delivery to help portfolio companies ensure that innovations translate directly into better patient care, thereby strengthening its market competitiveness.
- Revolution in Medical Robotics: Medical robotics has already transformed possibilities in the operating room, and the integration of AI is expected to further accelerate automation and performance improvements across care pathways, benefiting patients, clinicians, and health systems globally.
See More
Procept Scheduled to Announce Q1 Earnings with Mixed Estimates
- Earnings Announcement Date: Procept (PRCT) is set to release its Q1 2023 earnings on April 29th after market close, with consensus EPS estimate at -$0.56 and revenue estimate at $80.54 million, reflecting a 16.4% year-over-year growth.
- Performance Expectations: Over the past year, Procept has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, indicating stability in revenue but a need for improvement in profitability.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates, with 6 downward adjustments, and similarly, revenue estimates saw no upward revisions but 7 downward adjustments, suggesting market caution regarding the company's future performance.
- Long-term Revenue Goals: Procept has set a revenue target of $390 million to $410 million for 2026, and despite current performance missing expectations, the company aims to enhance its outlook through pricing discipline and commercial realignment, demonstrating confidence in future growth prospects.
See More
Procept Releases Financial Guidance for FY 2026
- Earnings Beat: Procept's Q1 GAAP EPS of $0.56 exceeds expectations by $1.12, indicating strong performance and improved profitability in the surgical robotics market.
- Significant Revenue Growth: The company reported Q1 revenue of $83.13 million, a 20.1% year-over-year increase, surpassing expectations by $2.59 million, reflecting sustained demand in the surgical robotics sector.
- 2026 Financial Guidance: Procept anticipates full-year 2026 revenue between $390 million and $410 million, representing a growth of 27% to 33% compared to the previous year, showcasing a positive outlook for future market conditions.
- Procedure Growth Expectations: The company expects U.S. procedure growth for 2026 to range from 39% to 48%, highlighting strong growth potential in the surgical robotics market and reinforcing its competitive position.
See More
Chicago Capital Increases Stake in PROCEPT BioRobotics
- Increased Holdings: Chicago Capital increased its stake in PROCEPT BioRobotics by 969,592 shares in Q1 2026, valued at approximately $27.32 million, bringing its ownership to 1.46%, indicating confidence in the company's growth potential.
- Stock Volatility: As of April 23, 2026, PROCEPT shares were priced at $24.24, down 56.5% year-over-year, reflecting significant volatility typical in the medical device sector, raising concerns about its profitability.
- Sales Growth: Since 2022, the number of procedures performed using PROCEPT's AquaBeam system surged from 7,400 to 43,000, while the installed base increased from 167 to 718, demonstrating strong market acceptance of its minimally invasive solutions.
- Improved Profitability: Although still unprofitable, PROCEPT's EBITDA margins improved from -91% to -16%, and gross margins rose from 49% to 64%, indicating the potential for future profitability and competitive strength in the market.
See More
Inogen Shares Surge 6.9% Driven by Buy Rating
- Price Surge Reason: Inogen (INGN) shares rose 6.9% in the last trading session to $6.8, with trading volume significantly above average, indicating increased investor interest in the stock.
- Buy Rating Impact: The initiation of a “Buy” rating by Freedom Broker, along with a substantial price target, has attracted new investors, driving the stock's rise and reflecting market confidence in the company's future growth.
- Governance Improvement Signal: The appointment of industry veteran Vafa Jamali to the board and a cooperation agreement with activist shareholder Kent Lake signal stronger strategic alignment and execution oversight, further boosting market confidence.
- Earnings Forecast: Inogen is expected to report a quarterly loss of $0.24 per share, representing a 4% year-over-year change, with revenues projected at $82.4 million, up 0.2%, reflecting the company's stability and potential growth in the medical instruments sector.
See More
Procept BioRobotics Lowers 2025 Revenue Guidance
- Revenue Growth Expectations: Procept BioRobotics guided for $325.5 million in 2025 revenue, projecting a 45% increase, yet reported only $308.1 million, falling short by $17.4 million, which caused shares to drop over 15% in a single day.
- Pricing Strategy Adjustment: The company implemented a pricing discipline initiative that eliminated historical bulk purchase discounts, resulting in a decrease in average selling prices to approximately $3,200 for its core product line, although the CFO stated this would not impede profitability progress.
- Dismal Future Outlook: The FY 2026 revenue guidance of $410 million to $430 million fell below analyst consensus, indicating pressure in market competition and uncertainty in profitability, which could undermine investor confidence.
- Shareholder Rights Protection: Following the stock decline, shareholders of Procept BioRobotics are encouraged to submit their information to discuss legal rights, indicating potential litigation risks for the company that may further impact its market reputation.
See More
Sonder Capital Closes Second Fund Futures II to Transform Patient Care
- Fund Size and Participants: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Collaborative Advantages: By collaborating with Mayo Clinic and Sutter Health, Sonder Capital can leverage insights from frontline care delivery to help portfolio companies ensure that innovations translate directly into better patient care, thereby strengthening its market competitiveness.
- Revolution in Medical Robotics: Medical robotics has already transformed possibilities in the operating room, and the integration of AI is expected to further accelerate automation and performance improvements across care pathways, benefiting patients, clinicians, and health systems globally.
See More
